You are viewing the site in preview mode

Skip to main content

Table 4 Adverse Events Associated With Rivastigmine*

From: Current pharmacologic options for patients with Alzheimer's disease

Adverse Event† Placebo (n = 868) (%) Rivastigmine 6–12 mg/day (n = 1189) (%)
Nausea 12 47
Vomiting 6 31
Anorexia 3 17
Dyspepsia 4 9
Asthenia 2 6
  1. * Novartis Pharmaceuticals Corp.: Exelon® (rivastigmine tartrate) capsules [prescribing information]. East Hanover, NJ 2001. † Occurring in at least 5% of patients and at twice the placebo rate.
Back to article page

Annals of General Psychiatry

ISSN: 1744-859X